

Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference

TEL AVIV, Israel, April 26, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in the Aegis Virtual Conference being held May 2-May 4, 2023. Chemomab management will present a corporate overview on Wednesday, May 3, 2023.

Aegis 2023 Virtual Investor Conference

Date: May 3, 2023
Time: 9:00am EDT
Venue: Virtual
Format: Webcast -- Corporate overview
Presenter: Senior management
Webcast Link: <https://us02web.zoom.us/j/81590540881>
Information: mschiavellojr@aegiscap.com

In addition, Chemomab reported that its corporate development team will be in Boston June 5-8, 2023, participating in the **BIO International Convention's One-on-One Partnering™** event. Registered attendees can click [here](#) to log in and schedule a meeting with Chemomab.

About Chemomab Therapeutics

Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury were recently reported. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing and a Phase 2 systemic sclerosis trial is expected to begin around midyear. For more information on Chemomab, visit chemomab.com.

Contacts:

Investors:

Irina Koffler
LifeSci Advisors, LLC
Phone: +1 (917) 734-7387
ir@chemomab.com

Investors & Media:

Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President, Investor & Public Relations
Strategic Communications
barbara.lindheim@chemomab.com

SOURCE Chemomab Therapeutics, Ltd.
